Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan and Dapagliflozin in CKD
NCT04724837Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of zibotentan in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Apr 2021; status: completed.
02
Drugs
zibotentan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04724837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04724837.